Atrial fibrillation and stroke prevention: where we are and where we should be.
作者信息
Jones Nicholas R, Hobbs Fd Richard, Taylor Clare J
机构信息
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.
出版信息
Br J Gen Pract. 2018 Jun;68(671):260-261. doi: 10.3399/bjgp18X696257.
Abstract
摘要
相似文献
1
Atrial fibrillation and stroke prevention: where we are and where we should be.心房颤动与卒中预防：我们所处的位置以及我们应达到的位置。
Br J Gen Pract. 2018 Jun;68(671):260-261. doi: 10.3399/bjgp18X696257.
2
Can the NICE guidelines on the management of atrial fibrillation improve its management?英国国家卫生与临床优化研究所（NICE）关于心房颤动管理的指南能否改善心房颤动的管理？
Clin Med (Lond). 2009 Jun;9(3):207-9. doi: 10.7861/clinmedicine.9-3-207.
3
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients.初治房颤患者中使用非维生素K拮抗剂口服抗凝剂
Europace. 2015 Feb;17(2):169-70. doi: 10.1093/europace/euu223. Epub 2014 Oct 23.
4
Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: cross-sectional population database study.口服抗凝药在心房颤动中的使用差异很大，且与估计的中风风险仅有微弱关联：横断面人群数据库研究。
Eur J Gen Pract. 2014 Sep;20(3):181-9. doi: 10.3109/13814788.2013.852535. Epub 2013 Dec 19.
5
Anticoagulation for Nonvalvular Atrial Fibrillation: Influence of Epidemiologic Trends and Clinical Practice Patterns on Risk Stratification and Net Clinical Benefit.非瓣膜性心房颤动的抗凝治疗：流行病学趋势和临床实践模式对风险分层及净临床获益的影响
Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9). doi: 10.1161/CIRCOUTCOMES.117.003669.
6
Stroke: Atrial fibrillation, stroke prevention therapy and aging.中风：心房颤动、中风预防治疗与衰老
Nat Rev Cardiol. 2009 Jul;6(7):448-50. doi: 10.1038/nrcardio.2009.98.
7
Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up.房颤患者在初级保健中的卒中风险再评估和口服抗凝剂的启动：十年随访。
Eur J Clin Invest. 2021 Jun;51(6):e13489. doi: 10.1111/eci.13489. Epub 2021 Jan 22.
8
[Atrial fibrillation in clinical practice: more answers are required].[临床实践中的心房颤动：需要更多答案]
Med Clin (Barc). 2013 Oct 5;141(7):295-6. doi: 10.1016/j.medcli.2013.04.007. Epub 2013 Jun 3.
9
Under-use of warfarin for patients with non-valvular atrial fibrillation in Japan.日本非瓣膜性心房颤动患者华法林使用不足。
Intern Med. 2004 Jul;43(7):529-30. doi: 10.2169/internalmedicine.43.529.
10
[Atrial fibrillation in clinical practice: more answers are required, but do we interpret properly the current evidence?].[临床实践中的心房颤动：需要更多答案，但我们是否正确解读了当前证据？]
Med Clin (Barc). 2014 Jan 7;142(1):43-4. doi: 10.1016/j.medcli.2013.07.018. Epub 2013 Oct 10.
引用本文的文献
1
Systematic in-silico evaluation of fibrosis effects on re-entrant wave dynamics in atrial tissue.系统计算纤维化对心房组织折返波动力学的影响。
Sci Rep. 2024 May 19;14(1):11427. doi: 10.1038/s41598-024-62002-5.
本文引用的文献
1
Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study.房颤抗凝治疗在英国临床委托组之间的差异：一项观察性研究。
Br J Gen Pract. 2018 Aug;68(673):e551-e558. doi: 10.3399/bjgp18X697913. Epub 2018 Jul 2.
2
2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50. doi: 10.1016/j.rec.2016.11.033.
3
Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.优化心房颤动患者的卒中预防：GRASP-AF审核工具在英国全科医疗队列中的应用
Br J Gen Pract. 2015 Jan;65(630):e16-23. doi: 10.3399/bjgp15X683113.
4
Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study.特定年龄的心房颤动相关栓塞性血管事件的发病率、结局、成本及预计未来负担：一项基于人群的研究。
Circulation. 2014 Oct 7;130(15):1236-44. doi: 10.1161/CIRCULATIONAHA.114.010942. Epub 2014 Sep 10.
5
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
6
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.华法林与阿司匹林用于老年社区房颤人群预防卒中的比较（伯明翰老年房颤治疗研究，BAFTA）：一项随机对照试验
Lancet. 2007 Aug 11;370(9586):493-503. doi: 10.1016/S0140-6736(07)61233-1.
7
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.不良事件对心房颤动患者华法林处方的影响：配对分析
BMJ. 2006 Jan 21;332(7534):141-5. doi: 10.1136/bmj.38698.709572.55. Epub 2006 Jan 10.
Zotero 插件